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(MRSA) has emerged as an important
nosocomial pathogen, accounting for
150% of all bloodstream S. aureus isolates
recovered from 49 representative US hos-
pitals [1], with similar trends in Europe
[2]. MRSA infection has also become
common in outpatients [3]. Even more
worrisome is the fact that MRSA was iden-
tified as the most common pathogen in
patients presenting with acute, purulent
skin and soft-tissue infections to emer-
gency departments in the United States
[4]. Such infections are associated with
longer hospital stays, longer durations of
antibiotic use, higher costs, and, probably,
greater mortality rates, compared with in-
fections caused by methicillin-susceptible
S. aureus [5, 6]. The emergence of com-
munity-onset MRSA infection aggravates
control of MRSA infection; a validated
guideline for control of community-onset
MRSA infection has not yet been pub-
lished, and community-onset MRSA in-
fection adds to the overall burden of
MRSA infection [7], even in countries
where a “search and destroy” policy is in
place [8]. From the United States, the pre-
dominant community-onset MRSA clone,
USA300 (ST8), can rapidly be spread by
travelers and health care workers in dif-
ferent parts of the world [9, 10]. Therefore,
new antimicrobial agents are urgently
needed [11].
The role of vancomycin as the reference
standard for treatment of MRSA infection
has been recently challenged [12]. In fact,
efficacy data have never been submitted
to the US Food and Drug Administration,
and breakpoints have recently been low-
ered by the Clinical and Laboratory Stan-
dards Institute to improve the correlation
between in vitro susceptibility and clinical
outcome. Many new drugs against gram-
positive pathogens—recently reviewed in
Clinical Infectious Diseases [13]—have
been developed, and some of them have
even been approved by the US Food and
Drug Administration (e.g., daptomycin,
tigecycline, and linezolid). However, ti-
gecycline and linezolid are bacteriostatic
rather than bactericidal. Bactericidal activ-
ity is important for therapeutic efficacy in
certain infections, such as endocarditis,
meningitis, and infections in neutropenic
patients. Although once-daily daptomycin
is bactericidal and approved for S. aureus
bacteremia, including endocarditis, it is
not active against S. aureus pneumonia
[14]. Other not yet approved drugs, such
as second-generation glycopeptides, have
a smaller spectrum of antimicrobial activ-
ity. Iclaprim, a folate inhibitor with bac-
tericidal activity against MRSA and gram-
negative pathogens, is still being studied
in clinical trials [15].
In infectious diseases, survival is signif-
icantly improved when the initial choice
of antibiotics is “appropriate,” which is
defined as all isolated pathogens being sus-
ceptible to 11 of the antimicrobial agents
administered [16]. In addition, multiple
studies provide strong evidence that rapid
therapy improves outcome, including that
of MRSA infection [6, 17, 18].
Complicated skin and skin-structure
infections and pneumonia are the most
frequently observed infections due to
community-onset MRSA. Currently, the
Infectious Diseases Society of America
guidelines recommend vancomycin or li-
nezolid for empirical treatment if MRSA
is suspected [19]. Microbiological results
require several days, and expensive PCR
tests must be performed to rule out MRSA
infection. Therefore, empirical coverage
for serious complicated skin and skin-
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structure infections requires coverage
against MRSA infection in hospitals and
in areas where MRSA infection is highly
endemic.
The carefully conducted randomized,
controlled clinical trial by Noel et al. [20]
provides strong evidence for noninferior-
ity of ceftobiprole, compared with the
combination of vancomycin and ceftazi-
dime, for treatment of complicated skin
and skin-structure infections. A similar
trial comparing ceftobiprole with vanco-
mycin alone supports the results of this
trial, with similar outcomes in both regi-
mens [21]. Other b-lactam antibiotics
with activity against MRSA are under de-
velopment, but no other agent is as ad-
vanced in clinical trial testing as ceftobi-
prole [22]. Ceftobiprole has an increased
binding to penicillin-binding protein 2a
from methicillin-resistant staphylococci
and to penicillin-binding protein 2x in a
penicillin-resistant Streptococcus pneu-
moniae strain, resulting in bactericidal ac-
tivity against these emerging pathogens. In
addition, ceftobiprole demonstrates activ-
ity against vancomycin-intermediate and
-resistant S. aureus [22]. Polymicrobial in-
fections are common in complicated skin
and skin-structure infections in patients
with diabetes; S. aureus, including MRSA,
and, less commonly, Pseudomonas aeru-
ginosa are most frequently identified as
causes of such infections. Culture findings
of swab specimens from an ulcer are dif-
ficult to interpret, but S. aureus and P.
aeruginosa should be covered for treat-
ment if found on culture of tissue speci-
mens or, preferably, bone biopsy speci-
mens. Ceftobiprole has in vitro activity
similar to that of ceftazidime or cefepime
against Enterobacteriaceae but is more ac-
tive towards AmpC-mediated b-lactam re-
sistance than is ceftriaxone or ceftazidime
[22]. Therefore, a single agent is now avail-
able for treatment that previously required
combinations of antibiotics. In such in-
fections, ceftobiprole may become the
drug of choice—if currently unknown ad-
verse effects do not limit its use in the
future.
Activity against enterococci is another
advantage of ceftobiprole. Enterococci are
frequent colonizers of foot ulcers in pa-
tients with diabetes but rarely require
treatment. However, serious infections are
encountered in the immunocompromised
host, in whom resistance to ampicillin and
vancomycin has emerged [23].
Ceftobiprole demonstrated a low po-
tential to select for resistance; the highest
MIC found in the presence of prolonged
serial passages with ceftobiprole at sub-
inhibitory concentrations was 8 mg/mL in
1 of 10 strains after 50 passages [24]. How-
ever, resistance will most likely emerge if
the drug is not used wisely. The adverse
effects associated with ceftobiprole are
similar to those associated with compa-
rators, with nausea and taste disturbance
(dysgeusia) being the most common.
Ceftobiprole may become an important
new antibiotic for complicated skin and
skin-structure infections before microbi-
ological results allow streamlining of an-
timicrobial therapy. MRSA coverage with
ceftobiprole may improve outcome by en-
abling early bactericidal therapy in pa-
tients admitted to emergency departments
because of complicated skin and skin-
structure infections not yet identified as
being due to MRSA. In addition, mixed
infections involving MRSA could be
treated with ceftobiprole, replacing van-
comycin-based combination therapy.
Available data do not allow clinical state-
ments against anaerobic infections. In vi-
tro activity indicates lower ceftobiprole
MICs for Acinetobacter and Alcaligenes
species, compared with ceftriaxone and
even cefepime [25], but ceftobiprole is not
likely to be suitable for gram-negative
pathogens expressing extended-spectrum
b-lactamases. Ceftobiprole has shown su-
periority to vancomycin in a rat model of
left-side MRSA endocarditis [26].
This promising new agent may be re-
garded as the first clinically effective ceph-
alosporin against MRSA for treatment of
complicated skin and skin-structure in-
fections, with 2 randomized clinical trials
supporting its efficacy [20, 21]. Its addi-
tional activity against ampicillin-suscep-
tible enterococci, penicillin-resistant
pneumococci, and most Enterobacteri-
aceae may allow ceftobiprole to be cate-
gorized as a new class of cephalosporins;
it may be considered to be a member of
the fifth-generation cephalosporins.
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